|
Just a quick update, I had an appointment yesterday to discuss a new mutation (Q252H) that has developed from the "Philadelphia chromosome" (9;22 translocation).This is very interesting. The nilotinib and previous dasatinib did not hold back this mutation leaving trace amounts of the cancer cells. So now I will be going back on Vidaza (7/28 days) and ponatinib (a "black box" chemo). So we'll see how that goes. My diagnosis (AML w/ Philadelphia chromosome) is extremely rare which makes this more interesting. There are no studies for my treatment and almost nothing in the literature so we are educationally "winging it". I have been feeling well and my CBCs and CMPs are about as good as any time in my life. Our insurance has been paying over $40,000 (not counting the cost of the BMBs) a month.
__________________
age 70, dx RAEB-2 on 11-26-2013 w/11% blasts. 8 cycles Vidaza 3w/Revlimid. SCT 8/15/2014, relapsed@Day+210 (AML). Now(SCT-Day+1005). Prepping w/ 10 days Dacogen for DLI on 6/9/2017.
|